  shares in zoetis inc nysezts acquired by endurant capital management lp  bnb daily daily ratings  news for zoetis inc complete the form below to receive the latest headlines and analysts recommendationsfor zoetis inc with our free daily email newsletter follow bnbdailynews recent posts paloma partners management co has  million stake in taiwan semiconductor manufacturing company ltd tsm paloma partners management co has  million stake in idex corporation iex paloma partners management co has  million stake in leidos holdings inc nyseldos  shares in zoetis inc nysezts acquired by endurant capital management lp jane street group llc has  stake in cna financial corporation cna crane company nysecr stake reduced by jane street group llc energen co nyseegn stake increased by jane street group llc jane street group llc purchases new stake in renasant corporation nasdaqrnst teleflex incorporated nysetfx stake held by glenmede trust co na crown castle international corporation nysecci stake held by glenmede trust co na glenmede trust co na has  stake in electronic arts inc nasdaqea ranger direct lending fund plc lonrdl insider acquires £ in stock colabor group inc tsegcl director acquires c in stock headtohead survey regal entertainment group nysergc and cinemark holdings cnk gannett co inc¿ nysegci upgraded to buy by bidaskclub eqt corporation eqt downgraded by royal bank of canada to sector perform inspired energy plc loninse stock rating reaffirmed by shore capital remax holdings inc rmax downgraded by bank of america corporation to “underperform” barclays plc cuts renewi plc sks price target to gbx  ritchie bros auctioneers incorporated rba trading down  following analyst downgrade  shares in zoetis inc nysezts acquired by endurant capital management lp posted by dan jones on jul rd   no comments endurant capital management lp purchased a new position in shares of zoetis inc nysezts during the first quarter according to its most recent form f filing with the securities and exchange commission sec the firm purchased  shares of the company’s stock valued at approximately  other hedge funds and other institutional investors have also added to or reduced their stakes in the company assetmark inc boosted its stake in zoetis by  in the first quarter assetmark inc now owns  shares of the company’s stock valued at  after buying an additional  shares during the period guardian life insurance co of america raised its position in zoetis by  in the first quarter guardian life insurance co of america now owns  shares of the company’s stock worth  after buying an additional  shares in the last quarter advisory services network llc bought a new position in zoetis during the first quarter worth approximately  first interstate bank raised its position in zoetis by  in the first quarter first interstate bank now owns  shares of the company’s stock worth  after buying an additional  shares in the last quarter finally israel discount bank of new york bought a new position in zoetis during the first quarter worth approximately  hedge funds and other institutional investors own  of the company’s stock zoetis inc nysezts opened at  on friday the stock’s  day moving average price is  and its  day moving average price is  the company has a market cap of  billion a pe ratio of  and a beta of  zoetis inc has a year low of  and a year high of  get zoetis inc alerts zoetis nysezts last announced its quarterly earnings results on thursday may th the company reported  earnings per share for the quarter beating analysts’ consensus estimates of  by  zoetis had a net margin of  and a return on equity of  the firm had revenue of  billion during the quarter compared to analysts’ expectations of  billion during the same period in the previous year the company earned  earnings per share zoetis’s quarterly revenue was up  compared to the same quarter last year on average equities analysts anticipate that zoetis inc will post  earnings per share for the current fiscal year the firm also recently announced a quarterly dividend which will be paid on friday september st stockholders of record on thursday june th will be issued a  dividend the exdividend date is tuesday june th this represents a  dividend on an annualized basis and a dividend yield of  zoetis’s payout ratio is  trademark violation notice “ shares in zoetis inc nysezts acquired by endurant capital management lp” was originally reported by bnb daily and is owned by of bnb daily if you are viewing this news story on another site it was copied illegally and republished in violation of international trademark  copyright laws the legal version of this news story can be read at httpswwwbaseballnewsblogcomendurantcapitalmanagementlpbuysnewstakeinzoetisincnyseztsupdatedupdatedhtml a number of equities analysts recently commented on the company cowen and company set a  price target on zoetis and gave the company a “buy” rating in a research note on monday july th deutsche bank ag reissued a “buy” rating and issued a  price target up from  on shares of zoetis in a research note on monday july th zacks investment research raised zoetis from a “hold” rating to a “buy” rating and set a  price target on the stock in a research note on tuesday june th hilliard lyons initiated coverage on zoetis in a research report on tuesday june th they set a “buy” rating and a  target price on the stock finally stifel nicolaus reaffirmed a “buy” rating and set a  target price on shares of zoetis in a research report on friday one analyst has rated the stock with a sell rating five have assigned a hold rating and thirteen have issued a buy rating to the company the stock has a consensus rating of “buy” and an average price target of  in other news insider catherine a knupp sold  shares of the company’s stock in a transaction dated friday may th the shares were sold at an average price of  for a total value of  following the completion of the sale the insider now directly owns  shares of the company’s stock valued at  the sale was disclosed in a filing with the securities  exchange commission which is available through this link  of the stock is currently owned by corporate insiders about zoetis zoetis inc is engaged in the discovery development manufacture and commercialization of animal health medicines and vaccines with a focus on both livestock and companion animals the company has a business commercializing products across eight core species cattle swine poultry sheep and fish collectively livestock and dogs cats and horses collectively companion animals and within five product categories antiinfectives vaccines parasiticides medicated feed additives and other pharmaceuticals receive news  ratings for zoetis inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for zoetis inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website endurant capital management lp company profile  bloomberg feedback endurant capital management lp private company company profile sector financials industry asset management subindustry investment management endurant capital management lp operates as an investment management company corporate information address  south grant street suite  san mateo ca  united states phone  fax  from the web key executives ajim akbar tamboli partneranalyst vishal saluja limited partnerportfolio mgr brian christopher ronan chris coochief compliance officer sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data endurant capital management lp ratings  rankings by symmetric home about pricing login endurant capital management lp register for more endurant capital overview endurant capital management lp is an investment advisor that manages  mm dollars in regulatory aum and has  employees of which  perform investment advisory functions the managers has disclosed holdings from  to  the funds latest filing disclosed mm in positions representing  of the managers regulatory aum unlock position crowdedness turnover  concentration endurant capital stockalpha  top  yr stockalpha register for more fundamental  technical factor exposure market cap beta volatility momentum m momentum m momentum m pricebook priceearnings pricecash flow dividend yield sales growth earnings growth roe roa roc ebidta margin debtassets hedge fund crowding endurant capital since last filing return details ticker size sector stock move stockalpha attribution days to liquidate trade crowdedness abt  health     bdx  health     unlock positions and returns details × register to unlock unlock profile and also get manager positions and return details position crowdedness turnover  concentration manager performance estimates top stock pickers report we take your privacy seriously your information will never be shared with any third party × download pdf report your requested report is being generated and will be emailed to you when ready if you do not receive the report please check your spam folder email infosymmetricio or call  featured in endurant capital founders and key employees name title in position since vishal saluja managing member and portfolio manager limited partner june quang m pham member and coportfolio manager june brian c ronan chief operating officer and chief compliance officer august ajim a tamboli partner and analyst august endurant capital brokers custodians auditors and administrators type company administrator pro auditor pro auditor pro custodian pro custodian pro custodian pro prime broker pro prime broker pro endurant capital investment strategy methods of analysis investment strategies and risk of loss investment strategy endurant capital’s core strategy is to generate steady riskadjusted returns by investing in companies in the health care industry endurant capital intends to target companies that fit one of the following criteria when investing in long positions a leading “quality” healthcare companies that generate strong free cash flow reinvest capital to sustain and accelerate topline and earnings growth and have a pathway to improving operating margins and therefore return on invested capital b companies typically small to midcap growth product companies that are on the cusp or early stages of a robust and sustainable product cycle such that the market does not fully appreciate the extent of the market opportunity or the strength of the underlying technology c companies that have typically been unfairly punished as a resulunlock full investment process description endurant capital portfolio concentration unlock portfolio concentration endurant capital location  s grant street suite  san mateo california united states  endurant capital contact information phone number  fax number  website null read recent symmetric reports disclaimer the information contained herein  is proprietary to symmetric andor its content providers  may not be copied or distributed and  is not warranted to be accurate complete or timely neither symmetric nor its content providers are responsible for any damages or losses arising from any use of this information past performance and skill metrics are no guarantee of future results symmetric symmetricio and the symmetric logo are marks of symmetric inc read our privacy policy here read our terms of use here path a halozyme therapeutics nasdaqhalo stock price news  analysis halozyme therapeutics company profile nasdaqhalo company profile analyst ratings earnings history earnings estimates dividend history insider trade headlines social media chart about halozyme therapeutics nasdaqhalo halozyme therapeutics inc is a biotechnology company focused on developing and commercializing oncology therapies the company operates in research development and commercialization of human enzymes and other drug candidates the companys segment also includes research and development activities and product sales of hylenex recombinant the companys development pipeline consists of clinicalstage product candidates in oncology its lead oncology program is pegph polyethylene glycol pegylated recombinant human hyaluronidase a molecular entity being developed for the systemic treatment of tumors which accumulate ha it is in phase ii and phase iii clinical testing for pegph in stage iv pancreatic ductal adenocarcinoma studies  and  phase ib clinical testing in nonsmall cell lung cancer study  and in phase ib clinical testing in nonsmall cell lung cancer and gastric cancer study  industry sector and symbol sector medical industry bio therapeutic drugs subindustry biotechnology symbol nasdaqhalo cusip h web wwwhalozymecom capitalizationmarket cap  billionoutstanding shares average prices day moving avg  day moving avg  week range    petrailing pe ratio naforeward pe ratio pe growth sales  book valueannual revenue  millionprice  sales book value  per shareprice  book  profitabilityebidta net margins return on assets debtdebttoequity ratio current ratio quick ratio miscaverage volume  million shsbeta short ratio    frequently asked questions for halozyme therapeutics nasdaqhalo what is halozyme therapeutics stock symbol halozyme therapeutics trades on the nasdaq under the ticker symbol halo how were halozyme therapeutics earnings last quarter halozyme therapeutics inc nasdaqhalo posted its earnings results on tuesday may th the company reported  eps for the quarter missing the zacks consensus estimate of  by  the firm earned  million during the quarter compared to analysts expectations of  million the firms revenue for the quarter was down  on a yearoveryear basis during the same quarter in the previous year the business earned  eps view halozyme therapeutics earnings history where is halozyme therapeutics stock going where will halozyme therapeutics stock price be in   equities research analysts have issued year price objectives for halozyme therapeutics shares their forecasts range from  to  on average they anticipate halozyme therapeutics stock price to reach  in the next year view analyst ratings for halozyme therapeutics who are some of halozyme therapeutics key competitors some companies that are related to halozyme therapeutics include intercept pharmaceuticals icpt juno therapeutics juno ultragenyx pharmaceutical rare gw pharmaceuticals plc gwph beigene bgne agios pharmaceuticals agio china biologic products cbpo sarepta therapeutics srpt avexis avxs prothena corporation plc prta axovant sciences axon spark therapeutics once loxo oncology loxo aerie pharmaceuticals aeri radius health rdus lexicon pharmaceuticals lxrx novocure limited nvcr and array biopharma arry who are halozyme therapeutics key executives halozyme therapeutics management team includes the folowing people connie l matsui chairman of the boardhelen i torley president chief executive officer directorlaurie d stelzer chief financial officer senior vice presidentmark j gergen jd chief operating officer senior vice presidentharry j leonhardt esq senior vice president chief compliance officer general counselathena m countouriotis md senior vice president chief medical officerjeanpierre bizzari md independent directorjames m daly independent directorjeffrey william henderson independent directorkenneth j kelley independent director who owns halozyme therapeutics stock halozyme therapeutics stock is owned by a variety of of retail and institutional investors top institutional shareholders include kirk randal j  fisher asset management llc  state of new jersey common pension fund d  taylor wealth management partners  nj state employees deferred compensation plan  and russell investments group ltd  view institutional ownership trends for halozyme therapeutics who sold halozyme therapeutics stock who is selling halozyme therapeutics stock halozyme therapeutics stock was sold by a variety of institutional investors in the last quarter including taylor wealth management partners fisher asset management llc and sit investment associates inc view insider buying and selling for halozyme therapeutics who bought halozyme therapeutics stock who is buying halozyme therapeutics stock halozyme therapeutics stock was bought by a variety of institutional investors in the last quarter including russell investments group ltd aperio group llc janney montgomery scott llc and creative planning view insider buying and selling for halozyme therapeutics how do i buy halozyme therapeutics stock shares of halozyme therapeutics can be purchased through any online brokerage account popular online brokerages include vanguard brokerage services td ameritrade etrade scottrade fidelity and charles schwab what is halozyme therapeutics stock price today one share of halozyme therapeutics stock can currently be purchased for approximately  marketbeat community rating for halozyme therapeutics nasdaq halocommunity ranking   out of    outperform votes   vote outperformunderperform votes   vote underperformtotal votes  marketbeats community ratings are surveys of what our community members think about halozyme therapeutics and other stocks vote outperform if you believe the stock will outperform the sp  over the long term vote underperform if you believe the stock will underperform the sp  over the long term you may vote once every thirty days analyst ratings consensus ratings for halozyme therapeutics nasdaqhalo how are consensus ratings calculated marketbeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months since brokers often use different ratings systems each rating is normalized to a standardized rating score of  sell  hold  buy or  strong buy consensus ratings scores are calculated using the mean average of the number of normalized sell hold buy and strong buy ratings each stocks consensus rating is derived from its calculated consensus ratings score   sell   hold   buy   strong buy marketbeats consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve monthsmarketbeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and marketbeat has received a report that coverage was dropped ratings from certain research firms that issue ratings using purely quantitative methods such as zacks vetr and valuengine are not included in consensus calculations marketbeats consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available dataratings breakdown  sell rating  hold ratings  buy ratingsconsensus ratingbuy score consensus price target   upside analysts ratings history for halozyme therapeutics nasdaqhalo show only the most recent rating from each brokerage all ratings for this stock datefirmactionratingprice targetimpact on share pricedetailscanaccord genuityset price targetbuyhighbarclays plcreiterated ratingoverweightlowbmo capital marketsinitiated coveragemarket performlowdeutsche bank agboost price targetbuy  lowpiper jaffray companiesreiterated ratingbuynacitigroup incdowngradebuy  neutralnajefferies group llcreiterated ratingsellnawells fargo  companyreiterated ratingbuynajmp securitieslower price targetmarket outperform  nadata available from  forward earnings earnings history for halozyme therapeutics nasdaqhaloearnings history by quarter for halozyme therapeutics nasdaq halodatequarterconsensus estimateactual epsrevenue estimateactual revenuerelease linkconference calldetailsq  million millionviewlistenq million millionviewlistenq million millionviewlistenq million millionviewnaq million millionviewnaq million millionviewlistenq million millionviewnaq million millionviewlistenq million millionviewlistenq million millionviewnaq million millionviewnaq million millionviewnaq million millionviewnaq million millionviewnaq million millionviewnaq  million millionviewnaq  million millionviewnaq  million millionviewnaq million millionviewnaviewnaviewnaviewnaviewnadata available from  forward estimates earnings estimates for halozyme therapeutics nasdaqhalo eps consensus estimate quarternumber of estimateslow estimatehigh estimateaverage estimateq q q q data provided by zacks investment research dividends dividend history for halozyme therapeutics nasdaqhalono dividend announcements for this company have been tracked by marketbeatcom insider trades insider trading and institutional ownership history for halozyme therapeutics nasdaqhaloinsider ownership percentage institutional ownership percentage insider trades by quarter for halozyme therapeutics nasdaqhalotransaction dateinsider nametitlebuysellnumber of sharesaverage share pricetotal transactiondetailslaurie stelzercfobuy  kenneth j kelleydirectorsell  david a ramsaycfobuy  helen torleyceobuy  john stuart pattondirectorsell  robert englerdirectorsell  john stuart pattondirectorsell  h michael shepardvpsell  kathryn falbergdirectorbuy  robert englerdirectorbuy  james p shaffervpbuy  kathryn e falbergdirectorbuy  kenneth j kelleydirectorbuy  gregory ian frostceobuy  data available from  forward headlines headline trends for halozyme therapeutics nasdaqhalo latest headlines for halozyme therapeutics nasdaqhalo source all sources trusted sources marketbeatcom bloomberg marketwatch motley fool nasdaq reuters seeking alpha the street the wall street journal yahoo finance dateheadlinehalozyme therapeutics inc breached its  day moving average in a bullish manner  halous  july  financeyahoocom  july  at  pmzacks analysts anticipate halozyme therapeutics inc nasdaqhalo will announce quarterly sales of  millionwwwamericanbankingnewscom  july  at  aminitiation of clinical trial collaboration evaluating halozymes pegph in combination with antipdl immunotherapy  pr newswire press releasewwwprnewswirecom  july  at  pm earnings per share expected for halozyme therapeutics inc nasdaqhalo this quarterwwwamericanbankingnewscom  july  at  pmhalozyme therapeutics halo announces initiation of clinical   streetinsidercomwwwstreetinsidercom  july  at  pminitiation of clinical trial collaboration evaluating halozymes pegph in combination with antipdl immunotherapyfinanceyahoocom  july  at  pminvestor thought martin shkreli was like rain man character because of his financial focusfinanceyahoocom  july  at  amhalozyme to host second quarter  financial results conference callfinanceyahoocom  july  at  pminvestor thought martin shkreli was like rain man character because of his financial focusfinanceyahoocom  july  at  pmformer shkreli employee says pharma bro was deeply depressed after hedge fund implodedfinanceyahoocom  july  at  ammartin shkreli worker called him mentally unstable threatened to expose lies by scam artistfinanceyahoocom  july  at  amformer officer of martin shkreli hedge fund filed sec complaint against shkreli while at fundfinanceyahoocom  july  at  ambriefhalozyme therapeutics unit entered into first amendment to amended restated lease with bmr   reuterswwwreuterscom  july  at  ammartin shkrelis lawyer and cowboy venture capitalist duel over value of horses and investmentsfinanceyahoocom  july  at  amformer shkreli employee says pharma bro was deeply depressed after hedge fund implodedfinanceyahoocom  july  at  amhalozyme therapeutics inc nasdaqhalo receives average recommendation of hold from brokerageswwwamericanbankingnewscom  july  at  pmhalozyme therapeutics inc nasdaqhalo downgraded to hold at bidaskclubwwwamericanbankingnewscom  july  at  pmhalozyme therapeutics inc breached its  day moving average in a bearish manner  halous  june  financeyahoocom  june  at  pmhalozyme phase  data in advanced pancreas cancer presented   pr newswire press releasewwwprnewswirecom  june  at  pmhalozyme phase  data in advanced pancreas cancer presented at european society for medical oncology symposiumfinanceyahoocom  june  at  pmdance biopharm appoints steve thornton to board of directorswwwprnewswirecom  june  at  pmhalozyme fda action date q review analysts outlook and price targetsfinanceyahoocom  june  at  pmetfs with exposure to halozyme therapeutics inc  june  financeyahoocom  june  at  pmhalozyme therapeutics inc halo lifted to strongbuy at bidaskclubwwwamericanbankingnewscom  june  at  pmfda approves genentechs rituxan hycela a subcutaneous rituximab coformulated with halozyme enhanze   pr newswire press releasewwwprnewswirecom  june  at  pmbarclays plc reiterates overweight rating for halozyme therapeutics inc halowwwamericanbankingnewscom  june  at  amhalozyme halo pleased by fda approval of genentechs rituxan hycelawwwstreetinsidercom  june  at  amfda approves genentechs rituxan hycela a subcutaneous rituximab coformulated with halozyme enhanze technologyfinanceyahoocom  june  at  am million in sales expected for halozyme therapeutics inc halo this quarterwwwamericanbankingnewscom  june  at  pm eps expected for halozyme therapeutics inc halo this quarterwwwamericanbankingnewscom  june  at  amhalozyme therapeutics inc breached its  day moving average in a bullish manner  halous  june  financeyahoocom  june  at  pmhalozyme therapeutics inc halo lifted to buy at bidaskclubwwwamericanbankingnewscom  june  at  pmnotable friday option activity finl x halowwwnasdaqcom  june  at  pmetfs with exposure to halozyme therapeutics inc  june  financeyahoocom  june  at  pmhalozyme therapeutics inc halous earnings analysis q  by the numbers  june  financeyahoocom  june  at  amhalozyme therapeutics inc halo short interest updatewwwamericanbankingnewscom  june  at  amhalozyme therapeutics inc halo receives average rating of hold from brokerageswwwamericanbankingnewscom  june  at  pmwhy halozyme therapeutics inc sank  in may  motley foolwwwfoolcom  june  at  pmhalozyme phase  data in advanced pancreas cancer featured in an oral presentation at asco  pr newswire press releasewwwprnewswirecom  june  at  pmhalozyme phase  data in advanced pancreas cancer featured in an oral presentation at ascofinanceyahoocom  june  at  pmhalozyme therapeutics inc halo rating increased to hold at valuenginewwwamericanbankingnewscom  june  at  pmzacks analysts expect halozyme therapeutics inc halo will announce quarterly sales of  millionwwwamericanbankingnewscom  may  at  amzacks brokerages expect halozyme therapeutics inc halo to post  epswwwamericanbankingnewscom  may  at  amhalozyme therapeutics announces completion of public offering and full wwwprnewswirecom  may  at  pmhalozyme therapeutics announces completion of public offering and full exercise of underwriters option to purchase additional sharesfinanceyahoocom  may  at  pmhalozyme pegph clinical development progress does not yet translate to valueseekingalphacom  may  at  pmhalozyme therapeutics inc breached its  day moving average in a bearish manner  halous  may  financeyahoocom  may  at  amhalozyme therapeutics halo prices m share offering at shwwwstreetinsidercom  may  at  pmmidday market update crude oil up  halozyme therapeutics shares plunge  nasdaqwwwnasdaqcom  may  at  pmhalozyme therapeutics incs necessary move sends shares down as much as   motley foolwwwfoolcom  may  at  pm social chart halozyme therapeutics halo chart for friday july   this page was last updated on  by marketbeatcom staff endurant capital management lp  relationship science news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink endurant capital management lp overview in the news executives  employees paths advisors  consultants holdings  top positions endurant capital management lp overview date founded  headquarters  south grant street suite  san mateo ca  employees worldwide  industries hedge funds investment services  portfolio management company description endurant capital management seeks to generate steady riskadjusted returns through longshort investments in small to midcap growth companies in the healthcare sector in the news see more see full news coverage and complete stories with relsci professional create your news feed see more executives  employees quang m pham cofounder vishal saluja cofounder chris ronan chief operating officer  chief compliance officer ajim akbar tamboli partner  analyst see our list of current and previous employees when you upgrade start my free trial ➤ see more paths to endurant capital management lp endurant capital management lp you connections via relationship science endurant capital management lp sync your contacts to see how you can connect with endurant capital management lp start my free trial ➤ see more advisors  consultants companies ▾ auditor kpmg llp kpmg llp provides audit tax  advisory services it serves in chemical healthcare media retail technology telecommunications and banking industries the firm has locations in africa asia australia europe north america and south america kpmg was founded in  and is headquartered in new york ny custodian morgan stanley  co llc founded in  morgan stanley  co llc is an secregistered brokerdealer headquartered in new york city the firm is the primary broker subsidiary of morgan stanley nyse ms they are a member of finra morgan stanley  co provides debt and equity services including underwriting ma advice securities dealing and brokerage and trade execution their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industrythe firms sales  trading division offers cash and electronic trading platforms where morgan stanley acts as principal including as a market maker and agent in executing transactions globally in equity and equityrelated products these products include equity swaps options warrants and futures overlying individual securities indices and baskets of securities and other equityrelated products morgan stanleys institutional equity division is a global leader in the origination distribution and trading of equity equitylinked and equityderivative securities their fixed income team deals in a diverse range of products including interest rate and currency products credit products derivatives and commodities holdings  top positions restricted data only for relsci professional users start my free trial ➤ see more youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ keryx biopharmaceuticals inc kerx raised to buy at zacks investment research  daily political home aboutcontact columnists privacy policy headlines politics nation world issues economy finance keryx biopharmaceuticals inc  get news  ratings daily enter your email address below to get the latest news and analysts ratings for keryx biopharmaceuticals inc with our free daily email newsletter follow dailypolitical     latest news rogers communication inc nyserci receives average rating of “buy” from brokerages zacks brokerages anticipate comerica incorporated nysecma will announce quarterly sales of  million cyberagent inc cygiy receives consensus rating of “” from brokerages atkins ws gbp watkf given consensus rating of “hold” by brokerages heidrick  struggles international inc nasdaqhsii rating lowered to strong sell at zacks investment research ilg inc nasdaqilg downgraded by zacks investment research to hold cys investments inc nysecys releases earnings results beats estimates by  eps critical contrast penn national gaming penn vs wynn resorts limited wynn brightcove inc nasdaqbcov releases quarterly earnings results misses estimates by  eps headtohead comparison ball corporation bll vs crown holdings cck contrasting holly energy partners lp hep  nustar gp holdings nsh zacks uacj corp uacjf given consensus recommendation of “sell” by analysts  earnings per share expected for dana incorporated dan this quarter somewhat positive press coverage somewhat unlikely to affect revlon nyserev stock price somewhat favorable press coverage somewhat unlikely to impact astec industries nasdaqaste share price somewhat positive media coverage somewhat unlikely to affect first busey corporation nasdaqbuse share price the ensign group nasdaqensg earning somewhat favorable press coverage accern reports somewhat positive press coverage somewhat unlikely to affect amarin corporation plc nasdaqamrn stock price biogen inc nasdaqbiib downgraded by vetr inc att inc nyset downgraded by vetr inc to “buy” keryx biopharmaceuticals inc kerx raised to “buy” at zacks investment research july th    comments  filed under  by patrick bannon filed under analyst articles  us  finance tweet zacks investment research upgraded shares of keryx biopharmaceuticals inc nasdaqkerx from a hold rating to a buy rating in a research report released on wednesday they currently have  price target on the biopharmaceutical company’s stock according to zacks “keryx intends to focus on the growth of auryxia in the us dialysis market meanwhile the company’s label expansion efforts on auryxia in the irondeficiency anemia ida indication seem to be encouraging given that the ida market holds great potential the fda accepted for review the supplemental new drug application snda for auryxia tablets for the same indication and has set the prescription drug user fee act pdufa target action date as nov    a potential approval should boost sales moreover shares of the company have outperformed the medicalbiomedgenetic market  in year to date however considering that the company is heavily dependent on auryxia for growth any further interruption in the supply of auryxia will hamper its growth trajectory going forward” several other brokerages have also commented on kerx maxim group raised their price target on shares of keryx biopharmaceuticals from  to  and gave the company a buy rating in a research note on monday may th valuengine cut shares of keryx biopharmaceuticals from a hold rating to a sell rating in a report on friday june nd finally cowen and company reiterated a hold rating on shares of keryx biopharmaceuticals in a report on saturday june th one research analyst has rated the stock with a sell rating six have issued a hold rating and five have assigned a buy rating to the company the stock currently has an average rating of hold and a consensus price target of  shares of keryx biopharmaceuticals kerx traded down  during midday trading on wednesday reaching  the company’s stock had a trading volume of  shares the stock has a  day moving average of  and a day moving average of  the company’s market capitalization is  million keryx biopharmaceuticals has a year low of  and a year high of  keryx biopharmaceuticals nasdaqkerx last announced its quarterly earnings results on thursday may th the biopharmaceutical company reported  eps for the quarter missing the consensus estimate of  by  keryx biopharmaceuticals had a negative net margin of  and a negative return on equity of  the firm had revenue of  million during the quarter compared to analyst estimates of  million during the same quarter in the previous year the business posted  eps keryx biopharmaceuticals’s revenue for the quarter was up  compared to the same quarter last year on average equities research analysts anticipate that keryx biopharmaceuticals will post  earnings per share for the current year illegal activity notice “keryx biopharmaceuticals inc kerx raised to “buy” at zacks investment research” was first reported by daily political and is the property of of daily political if you are reading this piece of content on another domain it was stolen and reposted in violation of us  international trademark  copyright laws the correct version of this piece of content can be viewed at httpswwwdailypoliticalcomkeryxbiopharmaceuticalsinckerxraisedtobuyatzacksinvestmentresearchhtml several hedge funds and other institutional investors have recently bought and sold shares of kerx lincoln capital corp bought a new position in keryx biopharmaceuticals during the fourth quarter valued at about  rice hall james  associates llc boosted its stake in shares of keryx biopharmaceuticals by  in the first quarter rice hall james  associates llc now owns  shares of the biopharmaceutical company’s stock worth  after buying an additional  shares during the last quarter janney montgomery scott llc boosted its stake in shares of keryx biopharmaceuticals by  in the first quarter janney montgomery scott llc now owns  shares of the biopharmaceutical company’s stock worth  after buying an additional  shares during the last quarter bank of montreal can acquired a new stake in shares of keryx biopharmaceuticals during the first quarter worth  finally metropolitan life insurance co ny boosted its stake in shares of keryx biopharmaceuticals by  in the fourth quarter metropolitan life insurance co ny now owns  shares of the biopharmaceutical company’s stock worth  after buying an additional  shares during the last quarter institutional investors and hedge funds own  of the company’s stock about keryx biopharmaceuticals keryx biopharmaceuticals inc is a biopharmaceutical company focused on the development of medicines for people with renal disease the company is engaged in the manufacture development and commercialization of products for use in treating human diseases its marketed product auryxia ferric citrate which is an orally available absorbable ironbased medicine is approved in the united states for the control of serum phosphorus levels in patients with chronic kidney disease ckd on dialysis get a free copy of the zacks research report on keryx biopharmaceuticals kerx for more information about research offerings from zacks investment research visit zackscom receive news  ratings for keryx biopharmaceuticals inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for keryx biopharmaceuticals inc and related companies with marketbeatcoms free daily email newsletter  comment on this post click here to cancel reply name required mail will not be published required website wordpress hashcash needs javascript to work but your browser has javascript disabled your comment will be placed in moderation latest news jeff sessions spoke of resigning after tensions increase with trump president trump’s tweets complicate already complicated week world leaders very critical of paris agreement decision by trump aide to president trump resigns with more expected scudclass missile launched by north korea  dailypolitical llc  all rights reserved privacy policy  about  columnists  contact endurant capital management lp  wealthminder endurant capital management lp endurant capital management lp crd  is a financial advisory firm headquartered in san mateo ca they manage  in  accounts and serve the financial needs of clients across  states or territories current firm details endurant capital management lp  s grant street suite  san mateo ca   by the numbers total assets under management  million total number of accounts  accounts average account value  compensation options a percentage of assets under your management other advisory services offered portfolio management for pooled investment vehicles other than investment companies types of clients registered states registered investment advisor advisors affiliated with a ria are permitted to work with up to five clients in nearlyall states without explicit registration the map below shows states where this firm has explicit registration only ca nj financial advisors at endurant capital management lp showing    of  top financial advisors  brian c ronan crd   s grant street suite  san mateo ca   wealthminder score brian ronan crd  is an investment advisor representative working at endurant capital management lp in san mateo ca and has over  years of experience in the finance industry  frank j laino crd  jamesburg nj  wealthminder score frank laino crd  is an investment advisor representative working at endurant capital management lp in jamesburg nj and has over  years of experience in the finance industry our primary data source is public filings of form adv as published by the securities and exchange commission sec and made available in accordance with the freedom of information act foia supplementary information may be provided by listed advisors or their representatives because many firms provide a variety of products or services an individual may or may not be registered to operate under all services provided by the firmdo not rely solely on the information on this page the information may be inaccurate incomplete or outdated for the most accurate and uptodate information please search for the firm or individual on the sec site at httpwwwadviserinfosecgoviapdcontentsearchiapdsearchaspx ready to hire a financial advisor get competitive proposals from multiple advisors request proposals timeout you have been idle and will be logged out in seconds stay logged in log out now endurant capital management lp  financial services firm san mateo california  brightscope advisor pages getsearchtypedisplaynamesearchtype advisor funds firms k plans back to top homefirmpagesendurant capital management lp endurant capital management lp overviewarticlesholdingsassetsservicesadvisorsleadershipfees share endurant capital management lp overviewarticlesholdingsassetsservicesadvisorsleadershipfees overview description endurant capital management lp is a ria based in san mateo ca with m in aum and with  advisors nationwide  vishal saluja is the majority owner of the firm and has been in this role with the firm since  information type ria head quarters san mateo ca  of employees  total assets  location  s grant st san mateo ca   articles insights there are no insights from this firm to display at this time procter  gamble plans competitive but exposure to company stock a risk to participants brightscope editorial firm links there are no links for this firm to display at this time holdings etf holdings there is no etf holding data from this firm to display at this time assets assets last updated on april   m total assets under management na total assets under advisement  accounts m estimated average account balance services firm services there is no services data available to display at this time firm client types advisors current advisors  of advisors  name start date brian christopher ronan october  frank joseph laino october  view all advisors leadership ownership there is no ownership data available to display at this time executives and control persons name title tenure date  ownership vishal saluja managing member and portfolio manager limited partner june   or more brian christopher ronan chief operating officer and chief compliance officer august  less than  ajim akbar tamboli partner and analyst august  less than  quang minh pham member and coportfolio manager june  less than  source sec fees types of compensation arrangements percentage of assets other company info about us newsroom careers contact blog explore k plan ratings advisor pages fund pages financial insights faq for advisors advisor pages spyglass for enterprise beacon social facebook twitter linkedin legal privacy policy terms of use copyright   brightscope inc all rights reserved your use of this service is subject to ourterms of useandprivacy policy information is provided as is and solely for informational purposes not for investment purposes or advicebrightscope is not a fiduciary under erisa brightscope is not endorsed by or affiliated with finra brightscope  cio  fww  global custodian  investor economics  liquidmetrix  market metrics  matrix solutions  planadviser  plan for life  plansponsor  simfund  strategic insight  the trade  strategic insight inc all rights reserved no reproduction without prior authorizations brightscope  advisor pages  find a financial advisor or advisory firm getsearchtypedisplaynamesearchtype advisor funds firms k plans general search advisors advisory firms financial qa k plans funds search home    brightscope advisor pages    find a financial advisory firm advisor search firm search advisors by city find a financial advisory firm search firm name active firms only city state alabama alaska american samoa arizona arkansas california colorado connecticut delaware district of columbia florida georgia guam hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota northern marinara islands ohio oklahoma oregon pennsylvania puerto rico rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming firm service areas financial planning estate planning comprehensive financial planning retirement planning college planning charitable planning other financial planning tax planning insurance life insurance health insurance longterm care insurance annuities property  casualty insurance business insurance other insurance pension consulting k b  defined benefit other pension consulting portfolio management individuals andor small businesses investment companies businesses or institutional clients other portfolio management accounting  tax tax advice other tax legal legal planning legal advice other legal other publication of periodicals or newsletters security ratings or pricing services market timing services selection of other advisors educational seminarsworkshops see all service areas find filters financialplanningfindfirm compensation arrangements no preference fixed fees  hourly charges  performancebased fees  none  fee only  assets under mgmt no preference   k  m  m  m  m  m  m  b  b  avg account balance no preference   k  k  k  k  m  m  m  m  m  financial advisory firm search results  results merrill lynch pierce fenner  smith incorporated ny ny  advisors  aum  b wells fargo advisors llc st louis mo  advisors  aum  b jp morgan securities llc manhattan ny  advisors  aum  b morgan stanley smith barney llc harrison ny  advisors  aum  b lpl financial llc boston ma  advisors  aum  b edward d jones  co lp des peres mo  advisors  aum  b ameriprise financial services inc minneapolis mn  advisors  aum  b ubs financial services inc weehawken nj  advisors  aum  b northwestern mutual investment servicesllc milwaukee wi  advisors charles schwab  co inc south beach ca  advisors mml investors services llc pine point ma  advisors  aum  b goldman sachs  co ny ny  advisors  aum  b strategic advisers inc boston ma  advisors  aum  b citigroup global markets inc new york ny  advisors  aum  b raymond james  associates inc st petersburg fl  advisors  aum  b      company info about us newsroom careers contact blog explore k plan ratings advisor pages fund pages financial insights faq for advisors advisor pages spyglass for enterprise beacon social facebook twitter linkedin legal privacy policy terms of use copyright   brightscope inc all rights reserved your use of this service is subject to ourterms of useandprivacy policy information is provided as is and solely for informational purposes not for investment purposes or advicebrightscope is not a fiduciary under erisa brightscope is not endorsed by or affiliated with finra brightscope  cio  fww  global custodian  investor economics  liquidmetrix  market metrics  matrix solutions  planadviser  plan for life  plansponsor  simfund  strategic insight  the trade  strategic insight inc all rights reserved no reproduction without prior authorizations endurant capital management lp  financial services firm san mateo california  brightscope advisor pages getsearchtypedisplaynamesearchtype advisor funds firms k plans back to top homefirmpagesendurant capital management lp endurant capital management lp overviewarticlesholdingsassetsservicesadvisorsleadershipfees share endurant capital management lp overviewarticlesholdingsassetsservicesadvisorsleadershipfees overview description endurant capital management lp is a ria based in san mateo ca with m in aum and with  advisors nationwide  vishal saluja is the majority owner of the firm and has been in this role with the firm since  information type ria head quarters san mateo ca  of employees  total assets  location  s grant st san mateo ca   articles insights there are no insights from this firm to display at this time procter  gamble plans competitive but exposure to company stock a risk to participants brightscope editorial firm links there are no links for this firm to display at this time holdings etf holdings there is no etf holding data from this firm to display at this time assets assets last updated on april   m total assets under management na total assets under advisement  accounts m estimated average account balance services firm services there is no services data available to display at this time firm client types advisors current advisors  of advisors  name start date brian christopher ronan october  frank joseph laino october  view all advisors leadership ownership there is no ownership data available to display at this time executives and control persons name title tenure date  ownership vishal saluja managing member and portfolio manager limited partner june   or more brian christopher ronan chief operating officer and chief compliance officer august  less than  ajim akbar tamboli partner and analyst august  less than  quang minh pham member and coportfolio manager june  less than  source sec fees types of compensation arrangements percentage of assets other company info about us newsroom careers contact blog explore k plan ratings advisor pages fund pages financial insights faq for advisors advisor pages spyglass for enterprise beacon social facebook twitter linkedin legal privacy policy terms of use copyright   brightscope inc all rights reserved your use of this service is subject to ourterms of useandprivacy policy information is provided as is and solely for informational purposes not for investment purposes or advicebrightscope is not a fiduciary under erisa brightscope is not endorsed by or affiliated with finra brightscope  cio  fww  global custodian  investor economics  liquidmetrix  market metrics  matrix solutions  planadviser  plan for life  plansponsor  simfund  strategic insight  the trade  strategic insight inc all rights reserved no reproduction without prior authorizations endurant capital management lp institutional portfolio  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search home  quotes  ownership  insider trades  institutional portfolio endurant capital management lp  s grant st san mateo california    report date  position statistics total positions  new positions  increased positions  decreased positions  positions with activity  sold out positions  total mkt value in  millions  institutional holdings information is filed by major institutions on form f with the securities and exchange commission sector weighting energy basic materials industrials consumer cyclicals consumer noncyclicals  financials  healthcare  technology telecommunication services utilities total positions new increased decreased activity sold out  positions as of  company class value of shares s ▼ change in value s change  shares held abbott labs com     becton dickinson  co com     aetna inc new com     unitedhealth group inc com     shire plc sponsored adr     universal hlth svcs inc cl b   new  anthem inc com     davita inc com     catalent inc com     jazz pharmaceuticals plc shs usd     oxford immunotec global plc ord shs     vwr corp com   new  celgene corp com     express scripts hldg co com     pfizer inc com     cardinal health inc com     allergan plc shs     thermo fisher scientific inc com     amerisourcebergen corp com     boston scientific corp com      first previousnext last  latest news headlines mercer international inc to present at upcoming jefferies  industrials conference pm et   globenewswire mediwound to host second quarter  financial results conference call on august   at  a pm et   globenewswire kors needs to buckle down for jimmy choo deal to shine am et   reuters vinci   halfyear financial report am et   globenewswire bombardier beats quarterly earnings expectations shares rise am et   reuters view all latest headlines closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex